Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
06:30am, Friday, 03'rd Feb 2023 GlobeNewswire Inc.
Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
Communiqué de presse : Forte performance des ventes, croissance à deux chiffres du BNPA et objectif de rentabilité atteint en 2022.
06:30am, Friday, 03'rd Feb 2023 GlobeNewswire Inc.
Forte performance des ventes, croissance à deux chiffres du BNPA et objectif de rentabilité atteint en 2022.
Santander Prepares for Rising Defaults as BoE Raises Interest Rate
03:05pm, Thursday, 02'nd Feb 2023
Santander UK has warned that macroeconomic challenges in the United Kingdom could impact credit quality. In its 2022 results announced on Thursday (Feb. 2), Santander UK revealed that it put aside 321
Banco Santander SA (SAN) Q4 2022 Earnings Call Transcript
10:41am, Thursday, 02'nd Feb 2023
Banco Santander SA (NYSE:SAN ) Q4 2022 Earnings Conference Call February 2, 2023 4:00 AM ET Company Participants Begona Morenes - IR Ana Botin - Group Executive Chairwoman Hector Grisi - Group CEO & G
'Proud of our results,' says Santander CEO as company beats interest income estimate
10:08am, Thursday, 02'nd Feb 2023
Ana Botin, executive chairman at Santander, discusses the company's results as Spain is facing a volatile year between strikes and upcoming political elections.
Santander readies itself for UK house price plunge
09:48am, Thursday, 02'nd Feb 2023
Santander set aside £321mln for mortgage repayment defaults in 2022 as the bank braces for housing prices to fall back. In 2023, a 10% fall in house prices is expected by the Spanish bank, driven by
Santander posts forecast-beating profit, revenue, upbeat on 2023
07:51am, Thursday, 02'nd Feb 2023 MarketWatch
The Spanish lender said it is targeting double-digit revenue growth and a return on tangible equity--a key measure of profitability--above 15% in 2023.
Santander posts forecast-beating profit, revenue, upbeat on 2023
02:51am, Thursday, 02'nd Feb 2023
Corrections & Amplifications
Santander books record 9.6 bln euro profit for 2022 but Q4 provisions up
02:28am, Thursday, 02'nd Feb 2023
Santander on Thursday said its 2022 net profit rose 18% to a record 9.6 billion euros ($10.6 billion) on higher lending, though results were overshadowed in the fourth quarter as provisions more than
Communiqué de presse: Dupixent® (dupilumab), premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement de l’œsophagite à éosinophiles
06:00am, Monday, 30'th Jan 2023 GlobeNewswire Inc.
Dupixent® (dupilumab), premier et seul médicament ciblé approuvé par la Commission européenne pour le traitement de l’œsophagite à éosinophiles
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
06:00am, Monday, 30'th Jan 2023 GlobeNewswire Inc.
Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
06:00am, Friday, 27'th Jan 2023 GlobeNewswire Inc.
Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
Communiqué de presse: Le CHMP recommande l’extension des indications de Dupixent® (dupilumab) dans l’UE au traitement de la dermatite atopique sévère du jeune enfant à partir de 6 mois
06:00am, Friday, 27'th Jan 2023 GlobeNewswire Inc.
Le CHMP recommande l’extension des indications de Dupixent® (dupilumab) dans l’UE au traitement de la dermatite atopique sévère du jeune enfant à partir de 6 mois
Communiqué de presse : Le NEJM publie des données de phase III sur l’efanesoctocog alpha une fois par semaine qui illustrent son potentiel à transformer le traitement de l’hémophilie A
10:30pm, Wednesday, 25'th Jan 2023 GlobeNewswire Inc.
